Higuchi Y
Department of Pharmacology, Kanazawa University School of Medicine, Takara-machi, Ishikawa.
Jpn J Cancer Res. 1996 Dec;87(12):1271-9. doi: 10.1111/j.1349-7006.1996.tb03143.x.
The Su strain of Streptococcus pyogenes (S-coccus)-derived anticancer preparation, OK-432, which is immobilized by heating in the presence of penicillin G, is well known to have an immunopotentiating activity through activation of natural killer cells in vivo. In this study, a streptococcal anticancer preparation stronger than OK-432 was prepared. Live streptococci (S-cocci) of the Su strain were induced to acquire H202-producing ability by treatment with serum under aerobic conditions. The resulting preparation no longer possessed hemolytic activity, and was not viable. The serum-treated S-coccus preparation activated natural killer cells as well as OK-432 did, and had stronger antitumor activity than OK-432 did. These results suggest that the serum-treated S-coccus preparation would be a useful tool for chemotherapy, in addition to immunotherapy, for the treatment of cancer.
化脓性链球菌(S 球菌)苏菌株衍生的抗癌制剂 OK-432,在青霉素 G 存在下经加热固定,众所周知其通过体内激活自然杀伤细胞具有免疫增强活性。在本研究中,制备了一种比 OK-432 更强的链球菌抗癌制剂。在有氧条件下用血清处理苏菌株的活链球菌(S 球菌),诱导其获得产生 H2O2 的能力。所得制剂不再具有溶血活性,且无活力。经血清处理的 S 球菌制剂与 OK-432 一样能激活自然杀伤细胞,并且具有比 OK-432 更强的抗肿瘤活性。这些结果表明,经血清处理的 S 球菌制剂除免疫疗法外,还将是癌症化疗的有用工具。